Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 102

Sort by

Sort Order Select

Journal Articles

Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) As Salvage Therapy for Patients with Multiple Myeloma: Multicenter, Retrospective Clinical Experience with 262 Cases Outside of Controlled Clinical Trials

Enrica Antonia Martino, Daniele Derudas, Elena Rossi, Sofia Terlizzi, Giovanni Reddiconto, Paola Stefanoni, Jacopo Micozzi, Silvia Mangiacavalli, Elena Zamagni, Massimo Offidani, Anna Furlan, Gabriele Buda, Sr., Flavia Lotti, Carmine Liberatore, Antonio Lazzaro, Roberta Della Pepa, Giuseppe Bertuglia, Emiliano Barbieri, Concetta Conticello, Claudio De Magistris, Lorenzo De Paoli, Velia Bongarzoni, Anna Maria Cafro, Anna Mele, Pietro Benvenuti, Claudio Cerchione, Cirino Botta, Elisabetta Antonioli, Nicola Sgherza, Sara Aquino, Giuseppe Mele, Gregorio Barila, Salvatore Palmieri, Ombretta Annibali, Rosario Bianco, Massimiliano Arangio Febbo, Gloria Margiotta Casaluci, Angela Rago, Raffaele Fontana, Francesca Farina, Ernesto Vigna, Antonella Bruzzese, Catello Califano, Angela Amendola, Daniela Roccotelli, Alessandra Lombardo, Annalisa Citro, Giuseppina Uccello, Renato Zambello, Alessandro Maggi, Santo Neri, Michele Monachesi, Alessandro Gozzetti, Vittorio Montefusco, Marino Brunori, Nicola Di Renzo, Marta Coscia, Valerio De Stefano, Antonino Neri, Francesco Di Raimondo, Fortunato Morabito, Pellegrino Musto, Massimo Gentile

Blood (2024) 144 (Supplement 1): 4699.

https://doi.org/10.1182/blood-2024-206008

Published: 2024

Journal Articles

Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition

Nico Gagelmann, Barbara Mora, Filippo Branzanti, Alessandro Maria Vannucchi, Massimo Breccia, Giuseppe Alberto Maria Palumbo, Massimiliano Bonifacio, Erika Morsia, Elena Maria Elli, Mario Tiribelli, Giulia Benevolo, Mirko Farina, Fabrizio Pane, Roberto Massimo Lemoli, Giovanni Caocci, Alessia Tieghi, Gianni Binotto, Francesco Cavazzini, Bruno Martino, Alessandro Isidori, Margherita Maffioli, Elisa Rumi, Tiziano Barbui, Francisco Cervantes, Matteo Giovanni Della Porta, Andrew T. Kuykendall, Marianna Caramella, Alessandra Iurlo, Valerio De Stefano, Jean-Jacques Kiladjian, David Ross, Jason Gotlib, Timothy Devos, Marco Ruggeri, Richard T. Silver, Rachel B. Salit, Thomas Schroeder, Carmelo Gurnari, Simona Pagliuca, Christina Rautenberg, Marie Robin, Marie-Thérèse Rubio, Jaroslaw Maciejewski, Alessandro Rambaldi, Maria Chiara Finazzi, Andrea Bacigalupo, Patrizia Chiusolo, Hans Christian Reinhardt, Bart L. Scott, Nicolaus Kröger, Francesco Passamonti, Francesca Palandri

Blood (2024) 144 (Supplement 1): 245.

https://doi.org/10.1182/blood-2024-210804

Published: 2024

Journal Articles

Familial Predisposition in Myeloproliferative Neoplasms: An NGS-Driven Analysis

Luca Di Marino, Francesco Ramundo, Tanja Malara, Monica Rossi, Roberto Maggi, Federica Fosso, Silvia Betti, Elena Rossi, Giuseppe Leone, Simona Sica, Valerio De Stefano, Patrizia Chiusolo

Blood (2024) 144 (Supplement 1): 1763.

https://doi.org/10.1182/blood-2024-210896

Published: 2024

Journal Articles

ROP-ET: A Prospective Phase III Trial Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythemia Patients with Limited Treatment Options

Blood (2024) 144 (Supplement 1): 6635.

https://doi.org/10.1182/blood-2024-199028

Published: 2024

Journal Articles

Revised ELN Criteria in Polycythemia Vera Identify an Increased Risk Phenotype for Thrombotic Events Beyond Conventional Risk Stratification. a Multicenter Cooperative Study

Blood (2024) 144 (Supplement 1): 242.

https://doi.org/10.1182/blood-2024-200528

Published: 2024

Journal Articles

ELN Criteria for Cytoreduction Start Identify Patients with Polycythemia Vera at Higher Thrombotic Risk

Blood (2023) 142 (Supplement 1): 4527.

https://doi.org/10.1182/blood-2023-181553

Published: 2023

Journal Articles

Prevention of CINV in Patients with Multiple Myeloma or Lymphoma Undergoing Hematopoietic Stem Cell Transplantation: NEPA Versus Ondansetron. a Monocentric Real-Life Experience

Blood (2023) 142 (Supplement 1): 7067.

https://doi.org/10.1182/blood-2023-187545

Published: 2023

Journal Articles

Ropeginterferon Alfa-2b Versus Standard Therapy for Low-Risk Patients with Polycythemia Vera. Final Results of Low-PV Randomized Phase II Trial

Blood (2022) 140 (Supplement 1): 1797–1799.

https://doi.org/10.1182/blood-2022-157255

Published: 2022

Journal Articles

Long Term Survival in Multiple Myeloma Patients: A Multicenter Italian Experience

Blood (2022) 140 (Supplement 1): 7147–7149.

https://doi.org/10.1182/blood-2022-165338

Published: 2022

Journal Articles

Safety and Survival Outcomes in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated with Lenalidomide-Based or Non-Lenalidomide-Based Treatments in the Real-World MM-034 Study

Michele Cavo, Sujith Dhanasiri, Valerio De Stefano, Angel Ramírez Payer, Martin Wiesholzer, Yvonne Tromp, Meegahage Ratnakanthi Perera, Valentine Richez-Olivier, Maciej Gil, David Bernasconi, Barbara Gamberi

Blood (2022) 140 (Supplement 1): 7195–7196.

https://doi.org/10.1182/blood-2022-162493

Published: 2022

Journal Articles

Prediction of Resistance to Hydroxyurea Therapy in Patients with Polycythemia Vera: A Machine Learning Study (PV-AIM)

Srdan Verstovsek, Florian H. Heidel, Valerio De Stefano, Mike Zuurman, Kenneth Bryan, Armita Afsharinejad, Jean-Jacques Kiladjian

Blood (2022) 140 (Supplement 1): 6823–6825.

https://doi.org/10.1182/blood-2022-157268

Published: 2022

Journal Articles

Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)

Tiziano Barbui, Alessandra Carobbio, Arianna Ghirardi, Alessandra Iurlo, Valerio De Stefano, Marta Anna Sobas, Elisa Rumi, Elena Maria Elli, Francesca Lunghi, Mercedes Gasior Kabat, Beatriz Cuevas, Paola Guglielmelli, Massimiliano Bonifacio, Monia Marchetti, Alberto Alvarez-Larran, Laura Maria Fox, Marta Bellini, Rosa Daffini, Giulia Benevolo, Gonzalo Carreño, Andrea Patriarca, Haifa Kathrin Al-Ali, Marcio Andrade, Francesca Palandri, Claire Harrison, Maria Angeles Foncillas, Santiago Osorio, Steffen Koschmieder, Elena Magro, Jean-Jacques Kiladjian, Estefanía Bolaños, Florian H. Heidel, Keina Quiroz, Martin Griesshammer, Valentín García Gutiérrez, Alberto Marin Sanchez, Juan Carlos Hernandez Boluda, Emma Lopez Abadia, Giuseppe Carli, Miguel Sagüés, Rajko Kusec, Blanca Xicoy, Margarita Guenova, Begoña Navas, Anna Angona, Edyta Cichocka, Anna Masternak, Daniele Cattaneo, Cristina Bucelli, Silvia Betti, Oscar Borsani, Fabrizio Cavalca, Sara Carbonell, Natalia Curto-Garcia, Lina Benajiba, Alessandro Rambaldi, Alessandro M. Vannucchi

Blood (2022) 140 (Supplement 1): 6815–6818.

https://doi.org/10.1182/blood-2022-158902

Published: 2022

Journal Articles

Risk Factors for Thrombosis in Patients Aged > 60 Years with Essential Thrombocythemia without Previous Thrombotic Events

Roberto Latagliata, Alessandro Andriani, Massimo Breccia, Ida Carmosino, Federico Vozella, Atelda Romano, Annalisa Biagi, Luca Maurillo, Malgorzata Monika Trawinska, Katia Paciaroni, Michelina Santopietro, Sabrina Leonetti Crescenzi, Ada D'Addosio, Caterina Tatarelli, Elisabetta Abruzzese, Ambra Di Veroli, Elena Rossi, Valerio De Stefano, Marco Montanaro

Blood (2022) 140 (Supplement 1): 9691–9692.

https://doi.org/10.1182/blood-2022-165356

Published: 2022

Journal Articles

Dosing Pattern of Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) in Italy: Results from a Prospective Observational Study (ROMEI)

Blood (2022) 140 (Supplement 1): 9688–9690.

https://doi.org/10.1182/blood-2022-157914

Published: 2022

Journal Articles

The Combination of Navitoclax and Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Mediates Responses Suggestive of Disease Modification

Francesco Passamonti, James M. Foran, Anand Tandra, Valerio De Stefano, Maria Laura Fox, Ahmad H. Mattour, Mary Frances McMullin, Andrew Charles Perkins, Gabriela Rodríguez-Macias, Hassan Sibai, Qin Qin, Yan Sun, Jalaja Potluri, Jason Harb, Jonathan How

Blood (2022) 140 (Supplement 1): 583–585.

https://doi.org/10.1182/blood-2022-157949

Published: 2022

Journal Articles

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

Blood (2022) 139 (19): 2931–2941.

https://doi.org/10.1182/blood.2021012743

Published: 2022

Includes: Supplemental data

Journal Articles

Neutrophil-to-Lymphocyte Ratio (NLR) Is a Risk Factor for Venous Thrombosis in Polycythemia Vera

Alessandra Carobbio, Alessandro Vannucchi, Paola Guglielmelli, Giuseppe Gaetano Loscocco, Ayalew Tefferi, Valerio De Stefano, Elena Rossi, Francesco Ramundo, Arianna Masciulli, Tiziano Barbui

Blood (2021) 138 (Supplement 1): 1499.

https://doi.org/10.1182/blood-2021-146793

Published: 2021

Journal Articles

Treatment of Portal, Mesenteric, and Splenic Vein Thrombosis with Rivaroxaban: A Pilot, Prospective Cohort Study

Blood (2021) 138 (Supplement 1): 671.

https://doi.org/10.1182/blood-2021-153813

Published: 2021

Journal Articles

Efficacy and Safety of Ruxolitinib in the Treatment of Elderly Patients with Policythemia Vera Resistant/Intolerant to Hydroxyurea

Blood (2021) 138 (Supplement 1): 2581.

https://doi.org/10.1182/blood-2021-149612

Published: 2021

Journal Articles

LocoMMotion: A Prospective, Non-Interventional, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed/Refractory Multiple Myeloma Who Received ≥3 Prior Lines of Therapy

Blood (2021) 138 (Supplement 1): 3057.

https://doi.org/10.1182/blood-2021-146188

Published: 2021

NARROW

Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) As Salvage Therapy for Patients with Multiple Myeloma: Multicenter, Retrospective Clinical Experience with 262 Cases Outside of Controlled Clinical Trials

Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition

Familial Predisposition in Myeloproliferative Neoplasms: An NGS-Driven Analysis

ROP-ET: A Prospective Phase III Trial Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythemia Patients with Limited Treatment Options

Revised ELN Criteria in Polycythemia Vera Identify an Increased Risk Phenotype for Thrombotic Events Beyond Conventional Risk Stratification. a Multicenter Cooperative Study

ELN Criteria for Cytoreduction Start Identify Patients with Polycythemia Vera at Higher Thrombotic Risk

Prevention of CINV in Patients with Multiple Myeloma or Lymphoma Undergoing Hematopoietic Stem Cell Transplantation: NEPA Versus Ondansetron. a Monocentric Real-Life Experience

Ropeginterferon Alfa-2b Versus Standard Therapy for Low-Risk Patients with Polycythemia Vera. Final Results of Low-PV Randomized Phase II Trial

Long Term Survival in Multiple Myeloma Patients: A Multicenter Italian Experience

Safety and Survival Outcomes in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated with Lenalidomide-Based or Non-Lenalidomide-Based Treatments in the Real-World MM-034 Study

Prediction of Resistance to Hydroxyurea Therapy in Patients with Polycythemia Vera: A Machine Learning Study (PV-AIM)

Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)

Risk Factors for Thrombosis in Patients Aged > 60 Years with Essential Thrombocythemia without Previous Thrombotic Events

Dosing Pattern of Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) in Italy: Results from a Prospective Observational Study (ROMEI)

The Combination of Navitoclax and Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Mediates Responses Suggestive of Disease Modification

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

Neutrophil-to-Lymphocyte Ratio (NLR) Is a Risk Factor for Venous Thrombosis in Polycythemia Vera

Treatment of Portal, Mesenteric, and Splenic Vein Thrombosis with Rivaroxaban: A Pilot, Prospective Cohort Study

Efficacy and Safety of Ruxolitinib in the Treatment of Elderly Patients with Policythemia Vera Resistant/Intolerant to Hydroxyurea

LocoMMotion: A Prospective, Non-Interventional, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed/Refractory Multiple Myeloma Who Received ≥3 Prior Lines of Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only